Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Enrico Alfei is active.

Publication


Featured researches published by Enrico Alfei.


American Journal of Medical Genetics Part A | 2011

The Pitt-Hopkins syndrome: report of 16 new patients and clinical diagnostic criteria.

Giuseppe Marangi; Stefania Ricciardi; Daniela Orteschi; Serena Lattante; Marina Murdolo; Bruno Dallapiccola; Chiara Biscione; Rosetta Lecce; Pietro Chiurazzi; Corrado Romano; Donatella Greco; Rosa Pettinato; Giovanni Sorge; Chiara Pantaleoni; Enrico Alfei; Irene Toldo; Cinzia Magnani; Paolo Bonanni; Federica Martinez; Gigliola Serra; Domenica Battaglia; Donatella Lettori; Gessica Vasco; Anna Baroncini; Cecilia Daolio; Marcella Zollino

Pitt‐Hopkins syndrome (PTHS) is characterized by severe intellectual disability, typical facial gestalt and additional features, such as breathing anomalies. Following the discovery of the causative haploinsufficiency of transcription factor 4 (TCF4), about 60 patients have been reported. We looked for TCF4 mutations in 63 patients with a suspected PTHS. Haploinsufficiency of TCF4 was identified in 14 patients, as a consequence of large 18q21.2 chromosome deletions involving TCF4 (2 patients), gene mutations (11 patients) and a t(14q;18q) balanced translocation disrupting TCF4 (one patient). By evaluating the clinical features of these patients, along with literature data, we noticed that, in addition to the typical facial gestalt, the PTHS phenotype results from the various combinations of the following characteristics: intellectual disability with severe speech impairment, normal growth parameters at birth, postnatal microcephaly, breathing anomalies, motor incoordination, ocular anomalies, constipation, seizures, typical behavior and subtle brain abnormalities. Although PTHS is currently considered to be involved in differential diagnosis with Angelman and Rett syndromes, we found that combining the facial characteristics with a detailed analysis of both the physical and the neurological phenotype, made molecular testing for PTHS the first choice. Based on striking clinical criteria, a diagnosis of PTHS was made clinically in two patients who had normal TCF4. This report deals with the first series of PTHS patients of Italian origin.


PLOS ONE | 2014

PDCD10 Gene Mutations in Multiple Cerebral Cavernous Malformations

Maria Sole Cigoli; Francesca Avemaria; Stefano De Benedetti; Giovanni P. Gesu; Lucio G iordano Accorsi; Stefano Parmigiani; Maria Franca Corona; Valeria Capra; Andrea Mosca; Simona Giovannini; Francesca Notturno; Fausta Ciccocioppo; Lilia Volpi; Margherita Estienne; Giuseppe De Michele; Antonella Antenora; Leda Bilo; Antonietta Tavoni; Nelia Zamponi; Enrico Alfei; Giovanni Baranello; Daria Riva; Silvana Penco

Cerebral cavernous malformations (CCMs) are vascular abnormalities that may cause seizures, intracerebral haemorrhages, and focal neurological deficits. Familial form shows an autosomal dominant pattern of inheritance with incomplete penetrance and variable clinical expression. Three genes have been identified causing familial CCM: KRIT1/CCM1, MGC4607/CCM2, and PDCD10/CCM3. Aim of this study is to report additional PDCD10/CCM3 families poorly described so far which account for 10-15% of hereditary cerebral cavernous malformations. Our group investigated 87 consecutive Italian affected individuals (i.e. positive Magnetic Resonance Imaging) with multiple/familial CCM through direct sequencing and Multiplex Ligation-Dependent Probe Amplification (MLPA) analysis. We identified mutations in over 97.7% of cases, and PDCD10/CCM3 accounts for 13.1%. PDCD10/CCM3 molecular screening revealed four already known mutations and four novel ones. The mutated patients show an earlier onset of clinical manifestations as compared to CCM1/CCM2 mutated patients. The study of further families carrying mutations in PDCD10/CCM3 may help define a possible correlation between genotype and phenotype; an accurate clinical follow up of the subjects would help define more precisely whether mutations in PDCD10/CCM3 lead to a characteristic phenotype.


Journal of Child Neurology | 2016

The diagnostic yield of array comparative genomic hybridization is high regardless of severity of intellectual disability/developmental delay in children

Stefano D'Arrigo; Francesco Gavazzi; Enrico Alfei; Orsetta Zuffardi; Cristina Montomoli; Barbara Corso; Erika Buzzi; Francesca L. Sciacca; Sara Bulgheroni; Daria Riva; Chiara Pantaleoni

Microarray-based comparative genomic hybridization is a method of molecular analysis that identifies chromosomal anomalies (or copy number variants) that correlate with clinical phenotypes. The aim of the present study was to apply a clinical score previously designated by de Vries to 329 patients with intellectual disability/developmental disorder (intellectual disability/developmental delay) referred to our tertiary center and to see whether the clinical factors are associated with a positive outcome of aCGH analyses. Another goal was to test the association between a positive microarray-based comparative genomic hybridization result and the severity of intellectual disability/developmental delay. Microarray-based comparative genomic hybridization identified structural chromosomal alterations responsible for the intellectual disability/developmental delay phenotype in 16% of our sample. Our study showed that causative copy number variants are frequently found even in cases of mild intellectual disability (30.77%). We want to emphasize the need to conduct microarray-based comparative genomic hybridization on all individuals with intellectual disability/developmental delay, regardless of the severity, because the degree of intellectual disability/developmental delay does not predict the diagnostic yield of microarray-based comparative genomic hybridization.


American Journal of Medical Genetics Part A | 2013

3q29 microdeletion syndrome: Cognitive and behavioral phenotype in four patients

Santina Città; Serafino Buono; Donatella Greco; Concetta Barone; Enrico Alfei; Sara Bulgheroni; Arianna Usilla; Chiara Pantaleoni; Corrado Romano

The 3q29 microdeletion syndrome is a rare, recurrent genomic disorder, associated with a variable phenotype, despite the same deletion size, consisting in neurodevelopmental features, such as intellectual disability (ID), schizophrenia, autism, bipolar disorder, depression and mild facial morphological anomalies/congenital malformations. A thorough neuropsychiatric evaluation has never been reported in patients with such syndrome. We analyzed the clinical phenotype of four individuals with 3q29 microdeletion syndrome, with special emphasis on the cognitive and behavioral assessment, in order to delineate the neuropsychiatric phenotype related to this condition. We assessed these patients with standardized scales or checklists measuring the cognitive (WISC III or LIPS‐R), behavioral (CBCL) and adaptive (VABS) performances. An accurate evaluation in our sample highlights different degrees of ID, variable behavioral disorders, and a preservation of communicative skills among remaining adaptive areas, as the neuropsychiatric hallmark of 3q29 microdeletion syndrome.


Brain | 2017

Mutations of AKT3 are associated with a wide spectrum of developmental disorders including extreme megalencephaly

Diana Alcantara; Andrew E. Timms; Karen W. Gripp; Laura Baker; Kaylee Park; Sarah Collins; Chi Cheng; Fiona Stewart; Sarju G. Mehta; Anand Saggar; László Sztriha; Melinda Zombor; Oana Caluseriu; Ronit Mesterman; Margot I. Van Allen; Adeline Jacquinet; Sofia Ygberg; Jonathan A. Bernstein; Aaron M. Wenger; Harendra Guturu; Gill Bejerano; Natalia Gomez-Ospina; Anna Lehman; Enrico Alfei; Chiara Pantaleoni; Valerio Conti; Renzo Guerrini; Ute Moog; John M. Graham; Robert F. Hevner

Mutations of genes within the phosphatidylinositol-3-kinase (PI3K)-AKT-MTOR pathway are well known causes of brain overgrowth (megalencephaly) as well as segmental cortical dysplasia (such as hemimegalencephaly, focal cortical dysplasia and polymicrogyria). Mutations of the AKT3 gene have been reported in a few individuals with brain malformations, to date. Therefore, our understanding regarding the clinical and molecular spectrum associated with mutations of this critical gene is limited, with no clear genotype-phenotype correlations. We sought to further delineate this spectrum, study levels of mosaicism and identify genotype-phenotype correlations of AKT3-related disorders. We performed targeted sequencing of AKT3 on individuals with these phenotypes by molecular inversion probes and/or Sanger sequencing to determine the type and level of mosaicism of mutations. We analysed all clinical and brain imaging data of mutation-positive individuals including neuropathological analysis in one instance. We performed ex vivo kinase assays on AKT3 engineered with the patient mutations and examined the phospholipid binding profile of pleckstrin homology domain localizing mutations. We identified 14 new individuals with AKT3 mutations with several phenotypes dependent on the type of mutation and level of mosaicism. Our comprehensive clinical characterization, and review of all previously published patients, broadly segregates individuals with AKT3 mutations into two groups: patients with highly asymmetric cortical dysplasia caused by the common p.E17K mutation, and patients with constitutional AKT3 mutations exhibiting more variable phenotypes including bilateral cortical malformations, polymicrogyria, periventricular nodular heterotopia and diffuse megalencephaly without cortical dysplasia. All mutations increased kinase activity, and pleckstrin homology domain mutants exhibited enhanced phospholipid binding. Overall, our study shows that activating mutations of the critical AKT3 gene are associated with a wide spectrum of brain involvement ranging from focal or segmental brain malformations (such as hemimegalencephaly and polymicrogyria) predominantly due to mosaic AKT3 mutations, to diffuse bilateral cortical malformations, megalencephaly and heterotopia due to constitutional AKT3 mutations. We also provide the first detailed neuropathological examination of a child with extreme megalencephaly due to a constitutional AKT3 mutation. This child has one of the largest documented paediatric brain sizes, to our knowledge. Finally, our data show that constitutional AKT3 mutations are associated with megalencephaly, with or without autism, similar to PTEN-related disorders. Recognition of this broad clinical and molecular spectrum of AKT3 mutations is important for providing early diagnosis and appropriate management of affected individuals, and will facilitate targeted design of future human clinical trials using PI3K-AKT pathway inhibitors.


Journal of Child Neurology | 2014

Novel Mutations in TSEN54 in Pontocerebellar Hypoplasia Type 2

Roberta Battini; Stefano D’Arrigo; Denise Cassandrini; Andrea Guzzetta; Chiara Fiorillo; Chiara Pantaleoni; Alessandro Romano; Enrico Alfei; Giovanni Cioni; Filippo M. Santorelli

Pontocerebellar hypoplasias represent a group of neurodegenerative autosomal recessive disorders characterized by hypoplasia/atrophy of the cerebellum, hypoplastic ventral pons, and microcephaly and associated with various clinical features. Pontocerebellar hypolasia type 2 is the most common form, and different mutations in genes encoding subunits of the transfer ribonucleic acid (RNA)–splicing endonuclease (TSEN) complex were identified in patients. The authors report clinical, imaging, and molecular studies in 2 unrelated patients with different clinical pictures of the pontocerebellar hypoplasia type 2 spectrum and novel mutations in TSEN54, aiming to further define the clinical spectrum of the disease and possible indicators of more favorable progression. They identified a novel missense mutation c.355T>G/p.Y119D in compound heterozygosity with the “common” c.919G>T/p.A307S (patient 1) and a novel homozygous c.7ins6(CCGGAG)/p.E2-P3insPE variant (patient 2). An expanded array of mutations might contribute in defining possible differences in severity and phenotype-genotype correlations.


European Journal of Paediatric Neurology | 2016

Chromosome 17q21.31 duplication syndrome: Description of a new familiar case and further delineation of the clinical spectrum

Federica Natacci; Enrico Alfei; Lucia Tararà; Stefano D'Arrigo; Orsetta Zuffardi; Barbara Gentilin; Chiara Pantaleoni

INTRODUCTION 17q21.31 microduplication syndrome is a recently described condition associated with a broad clinical spectrum, of which psychomotor delay, behavioral disorders and poor social interaction seem to be the most consistent features. Only seven patients have been reported thus far. All have behavioral disorders reminiscent of the autistic spectrum with intellectual skills ranging from normal to mild intellectual deficiency. Other features are variable with no striking common phenotypic features. CASE STUDY Here we describe the segregation of 17q21.31 duplication in an Italian family. DISCUSSION Clinical features and genetic data are reported, and compared with previously reported patients with 17q21.31 microduplication. A comparison of clinical manifestations between deletion and duplication syndromes of the chromosome regione is provided.


American Journal of Medical Genetics Part A | 2017

ZC4H2 deletions can cause severe phenotype in female carriers

Cristina Zanzottera; Donatella Milani; Enrico Alfei; Ambra Rizzo; Stefano D'Arrigo; Susanna Esposito; Chiara Pantaleoni

ZC4H2 is involved in human brain development, and, if mutated, can be responsible for a rare X‐linked disorder, originally presented in literature as Wieacker–Wolff syndrome and Miles–Carpenter syndrome. In males, severe intellectual disability is associated with variable symptoms of central and peripheral nervous system involvement, such as spasticity, hyperreflexia, muscle weakness, and arthrogryposis. Female carriers are usually described as asymptomatic or only mildly affected. Here, we report on a girl carrying a de novo deletion of ZC4H2 detected by array‐CGH analysis. She showed a complex neurodevelopmental disorder resembling the clinical picture commonly observed in male patients. X‐inactivation was found to be random. Additionally, she had an unusual appearance of fingers and hand creases, and electromyography showed a peculiar pattern of both neurogenic and myopathic anomalies. The present patient confirms that female carriers can also be severely affected. Systematic clinical investigations of both males and females are needed to define the variety in nature and severity of phenotypes related to ZC4H2 variants.


Congenital Anomalies | 2016

Insights into 6q21‐q22: Refinement of the critical region for acro‐cardio‐facial syndrome

Donatella Milani; Giulia Anna Cagnoli; Marco Baccarin; Enrico Alfei; Silvana Guerneri; Susanna Esposito

Deletions on chromosome 6q are rarely reported in the literature, and genotype‐phenotype correlations are poorly understood. We report a child with a deletion of the 6q21‐q22 chromosomal region, providing some intriguing results about the correlation between this region and acro‐cardio‐facial syndrome, congenital heart disease, split hand and foot malformation, and epilepsy.


American Journal of Medical Genetics Part A | 2014

Seizures and EEG features in 74 patients with genetic‐dysmorphic syndromes

Enrico Alfei; Federico Raviglione; Silvana Franceschetti; Stefano D'Arrigo; Donatella Milani; Angelo Selicorni; Daria Riva; Orsetta Zuffardi; Chiara Pantaleoni; Simona Binelli

Epilepsy is one of the most common findings in chromosome aberrations. Types of seizures and severity may significantly vary both between different conditions and within the same aberration. Hitherto specific seizures and EEG patterns are identified for only few syndromes. We studied 74 patients with defined genetic‐dysmorphic syndromes with and without epilepsy in order to assess clinical and electroencephalographic features, to compare our observation with already described electro‐clinical phenotypes, and to identify putative electroencephalographic and/or seizure characteristics useful to address the diagnosis. In our population, 10 patients had chromosomal disorders, 19 microdeletion or microduplication syndromes, and 32 monogenic syndromes. In the remaining 13, syndrome diagnosis was assessed on clinical grounds. Our study confirmed the high incidence of epilepsy in genetic‐dysmorphic syndromes. Moreover, febrile seizures and neonatal seizures had a higher incidence compared to general population. In addition, more than one third of epileptic patients had drug‐resistant epilepsy. EEG study revealed poor background organization in 42 patients, an excess of diffuse rhythmic activities in beta, alpha or theta frequency bands in 34, and epileptiform patterns in 36. EEG was completely normal only in 20 patients. No specific electro‐clinical pattern was identified, except for inv‐dup15, Angelman, and Rett syndromes. Nevertheless some specific conditions are described in detail, because of notable differences from what previously reported. Regarding the diagnostic role of EEG, we found that—even without any epileptiform pattern—the generation of excessive rhythmic activities in different frequency bandwidths might support the diagnosis of a genetic syndrome.

Collaboration


Dive into the Enrico Alfei's collaboration.

Top Co-Authors

Avatar

Chiara Pantaleoni

Carlo Besta Neurological Institute

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Donatella Milani

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giovanni Baranello

The Catholic University of America

View shared research outputs
Top Co-Authors

Avatar

Daria Riva

Carlo Besta Neurological Institute

View shared research outputs
Top Co-Authors

Avatar

Chiara Fiorillo

Istituto Giannina Gaslini

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Federica Natacci

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

View shared research outputs
Researchain Logo
Decentralizing Knowledge